Oro-mucosal drug delivery company, SUDA Pharmaceuticals Limited (ASX:SUD) released its quarterly report for the three-month period ended 31st March 2020. The Company highlighted the following key developments for the March quarter:
- Commencement of Dr Michael Baker’s role as SUDA’s CEO.
- Appointment of General Manager for Perth operations.
- Signing of a new licence pact with MTPK (Mitsubishi Tanabe Pharma Korea Ltd) pertaining to ZolpiMist.
- Kicking off feasibility studies with Ordesa and Sanofi.
The Company’s cash receipts stood at $323,000 for the quarter, with a bank balance of $1,508,000 at 31st March 2020.
As at 12:07 PM AEST on 30th April 2020, SUD is trading at $0.049 with a rise of ~2.1 per cent.
Disclaimer
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.
